
    
      To evaluate efficacy of extend treatment during 24 weeks more in co-infected HIV-HCV patients
      with genotype 1 and/or 4 who at 44 week of treatment with peginterfer√≥n alfa-2a in
      combination with ribavirin have RNA-HCV undetectable.
    
  